Prion Protein as a Receptor for Amyloid-Beta Oligomers

Patent metadata

Field	Value
Publication number	US-2016176972-A1
Application number	US-201514974442-A
Country	US
Kind code	A1
Filing date	Dec 18, 2015
Priority date	Apr 26, 2007
Publication date	Jun 23, 2016
Grant date	—

Abstract

The invention provides methods of inhibiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrP c antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinations, as well as methods of identifying molecules that could function as PrP c antagonists.

First claim

What is claimed is:

1 . A method comprising administering a therapeutically effective amount of a PrP c antagonist to a subject having Alzheimer's disease (AD), wherein said PrP c antagonist comprises an anti-PrP c antibody, or antigen-binding fragment thereof, which specifically binds to an epitope within amino acids 95 to 110 of SEQ ID NOs:2, 4, or 6.

2 . The method of claim 1 , wherein said anti-PrP c antibody is a monoclonal antibody (mAb).

3 . The method of claim 2 , wherein the mAb is selected from the group consisting of a humanized antibody, a chimeric antibody, a human antibody, and antigen-binding fragments of any of the foregoing.

4 . The method of claim 2 , wherein said monoclonal antibody is 6D11.

5 . The method of claim 2 , wherein said monoclonal antibody is 8G8.

6 . The method of claim 2 , wherein said anti-PrP c antibody specifically binds to the same epitope as 6D11.

7 . The method of claim 2 , wherein said anti-PrP c antibody specifically binds to the same epitope as 8G8.

8 . The method of claim 1 , further comprising administering an additional therapeutic agent.

9 . A method comprising administering a therapeutically effective amount of a PrP c antagonist to a subject having Alzheimer's disease (AD), wherein said PrP c antagonist comprises an anti-PrP c antibody, or antigen-binding fragment thereof, which specifically binds to an epitope within amino acids 32 to 121 of SEQ ID NOs:2, 4, or 6.

10 . The method of claim 9 , wherein said anti-PrP c antibody is a monoclonal antibody (mAb).

11 . The method of claim 10 , wherein the mAb is selected from the group consisting of a: humanized antibody, a chimeric antibody, a human antibody, and antigen-binding fragments of any of the foregoing.

12 . The method of claim 9 , further comprising administering an additional therapeutic agent.

Assignees

• Univ Yale

Inventors

• Strittmatter Stephen M
• Lauren Juha
• Gimbel David

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61K2039/505

  comprising antibodies · CPC title